General
Preferred name
MINALRESTAT
Synonyms
ARI509 ()
WAY-121509 ()
WAY121509 ()
WAYARI-509 ()
ARI-509 ()
WAY-ARI-509 ()
Minalrestat ()
P&D ID
PD069227
CAS
155683-53-7
129688-50-2
Tags
available
drug candidate
Drug indication
Diabetic complication
Drug Status
investigational
Max Phase
2.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PRICE
857
DESCRIPTION
Minalrestat is an aldose reductase inhibitor originated by Wyeth. In Aug 2002, Phase-III for Diabetic retinopathy was discontinued in USA and Europe.
(BOC Sciences Bioactive Compounds)
DESCRIPTION
Minalrestat(ARI-509) is an orally active and potent aldose reductase inhibitor for the study of impaired microvascular reactivity in diabetic patients.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
6
BOC Sciences Bioactive Compounds
ChEMBL Drugs
DrugMAP
DrugMatrix
LSP-MoA library (Laboratory of Systems Pharmacology)
TargetMol Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
18
Molecular Weight
447.99
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
1
Rotatable Bonds
2
Ring Count
4
Aromatic Ring Count
2
cLogP
2.19
TPSA
83.55
Fraction CSP3
0.16
Chiral centers
1.0
Largest ring
6.0
QED
0.56
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
Aldose Reductase
Pathway
Endocrinology/Hormones
Metabolism
Solubility
Soluble in DMSO
Source data
